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Testicular germ cell tumor (TGCT) is the most common cancer in young men. Despite a considerable familial
component to TGCT risk, no genetic change that confers increased risk has been substantiated to date. The human
Y chromosome carries a number of genes speciﬁcally involved in male germ cell development, and deletion of the
AZFc region at Yq11 is the most common known genetic cause of infertility. Recently, a 1.6-Mb deletion of the
Y chromosome that removes part of the AZFc region—known as the “gr/gr” deletion—has been associated with
infertility. In epidemiological studies, male infertility has shown an association with TGCT that is out of proportion
with what can be explained by tumor effects. Thus, we hypothesized that the gr/gr deletion may be associated
with TGCT. Using logistic modeling, we analyzed this deletion in a large series of TGCT cases with and without
a family history of TGCT. The gr/gr deletion was present in 3.0% (13/431) of TGCT cases with a family history,
2% (28/1,376) of TGCT cases without a family history, and 1.3% (33/2,599) of unaffected males. Presence of
the gr/gr deletion was associated with a twofold increased risk of TGCT (adjusted odds ratio [aOR] 2.1; 95%
conﬁdence interval [CI] 1.3–3.6; Pp .005) and a threefold increased risk of TGCT among patients with a positive
family history (aOR 3.2; 95% CI 1.5–6.7; P p .0027). The gr/gr deletion was more strongly associated with
seminoma (aOR 3.0; 95% CI 1.6–5.4; P p .0004) than with nonseminoma TGCT (aOR 1.5; 95% CI 0.72–3.0;
Pp .29). These data indicate that the Y microdeletion gr/gr is a rare, low-penetrance allele that confers susceptibility
to TGCT.
Introduction
Testicular germ cell tumor (TGCT [MIM 273300]) is
the most common cancer in men aged 15–40 years. The
worldwide incidence is 7.5 per 100,000, but rates vary
between countries, with the highest incidence among
men of European descent (Huyghe et al. 2003; Jemal et
al. 2004). The incidence of TGCT has more than dou-
bled over the past 50 years; however, the underlying
etiology is unknown (Davies 1981; Adami et al. 1994;
Bergstrom et al. 1996; Bosl et al. 1997). Family history
is among the strongest known risk factors for TGCT,
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with multiple studies documenting that brothers and fa-
thers of patients with TCGT have an 8–12-fold and a
4–6-fold increased risk, respectively (Forman et al. 1992;
Heimdal et al. 1996; Westergaard et al. 1996; Sonneveld
et al. 1999; Hemminki and Li 2004). These relative risks
are stronger than those for most other cancer types
(Hemminki and Eng 2004), suggesting that there is a
substantial genetic contribution to TGCT susceptibility.
Additional risk factors for the development of TGCT
include previous TGCT, undescended testes (UDT
[MIM 219050]), gonadal dysgenesis (MIM 233430),
hypospadius (MIM 146450), hernia, and male infertil-
ity (Schottenfeld et al. 1980; Moller and Skakkebaek
1996; Petersen et al. 1998b; Akre et al. 1999). Patients
with TGCT often present with abnormal semen char-
acteristics beyond those that can be easily explained by
localized or systemic effects of the tumor, and TGCT is
found at increased frequency among men who showed
abnormal results on semen analysis (Petersen et al.
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Table 1
Prevalence of the gr/gr Deletion in TGCT-Affected and Unaffected
Males
SUBJECT GROUP
PREVALENCE OF gr/gr
DELETION
n %
Probands of multiple-case familiesa:
ITCLC family probands 13/396 3.3
Case-series family probandsb 0/35 0
Total 13/431 3.0
TGCT sporadic case seriesc:
London 12/419 2.9
Leeds (United Kingdom) 2/263 .8
Rotterdam 4/311 1.3
Toronto 2/14 14.3
Hungary 0/18 0
Other (Germany, Ireland, and Russia)d 0/8 0
Total 20/1,033 1.9
TGCT sporadic cases from case-control series:
Philadelphia 3/99 3.0
Washington Statee 5/167 3.0
Total 8/266 3.0
Affected individuals:
With solitary TGCTf 0/17 0
With bilateral TGCTg 0/61 0
Total 0/78 0
Unaffected males:
U.K. control series I 3/135 2.2
U.K. control series II 1/514 .2
U.K. control series III 1/225 .4
U.K. control series IV 7/400 1.7
Philadelphia 5/518 .9
Washington State 8/435 1.6
Hungary 8/394 2.0
Total 33/2,599 1.3
a Excludes one member from each of 12 MZ twin pairs.
b Nine of the case-series probands were part of the ITCLC and are
included in table 2.
c Individuals with solitary or bilateral TGCT and no family history
of TGCT.
d These sites are contributors to the ITCLC.
e Does not include 23 individuals with unknown family history.
f Patients ascertained because of family history of UDT.
g Patients ascertained as bilateral cases with no family history of
TGCT.
1998a; Jacobsen et al. 2000). It has been documented
that patients with TGCT have lower fecundity than that
of healthy controls (Moller and Skakkebaek 1999; Ri-
chiardi et al. 2004). Given the link between male in-
fertility and TGCT—and the fact that familial aggre-
gation has also been demonstrated for male infertility—
genetic factors may exist that contribute to both con-
ditions (Lilford et al. 1994).
Microdeletions of the Y chromosome are the most
common known cause of infertility due to spermato-
genic failure and account for ∼10% of cases (Vogt et
al. 1996; Kuroda-Kawaguchi et al. 2001). Male infer-
tility has been associated with speciﬁc deletions of Yq11:
AZFa, -b, and -c (MIM 415000). The AZF deletions
are due to recombination between large palindromic
sequences that have 199.9% identity and are composed
of long, direct and indirect repeats called “amplicons”
(Vogt et al. 1996; Kuroda-Kawaguchi et al. 2001; Ska-
letsky et al. 2003). The ampliconic portion of the male-
speciﬁc Y (MSY) region of the human Y chromosome
contains a high density of genes from nine gene families,
with each gene existing in multiple (2–35) near-identical
copies (Skaletsky et al. 2003). Genes within the ampli-
conic portion of the MSY are expressed predominantly
or exclusively in the testis and are believed to contrib-
ute to the development and proliferation of germ cells
(Reijo et al. 1995). Given the important function of
these genes in spermatogenesis, the known deletions in
the region, and the link between infertility and TGCT,
it has been postulated that the deletions in AZF might
be associated with TGCT. However, neither AZF de-
letions nor Y-chromosome haplotypes have previously
been associated with TGCT case status (Frydelund-Lar-
sen et al. 2003; Quintana-Murci et al. 2003).
A novel, Y-chromosome 1.6-Mb deletion, designated
“gr/gr,” was described recently and has been found to
be associated with spermatogenic failure (Repping et al.
2003; Machev et al. 2004; de Llanos et al. 2005; Ferlin
et al. 2005; Hucklenbroich et al. 2005; Lynch et al.
2005). The gr/gr deletion removes part of the AZFc
region, including two copies of DAZ (deleted in azo-
spermia [MIM 400003]) and one copy of CDY1 (chro-
modomain protein, Y-linked 1 [MIM 400016]), as well
as several other transcription units. Since father-to-son
transmission is observed, the gr/gr deletion likely results
in subfertility rather than complete infertility. The de-
letion was observed to be in association with numerous
Y haplotypes, which suggests multiple independent re-
combination events (Repping et al. 2003). We hypoth-
esized that the gr/gr deletion may play a role in TGCT
susceptibility, and we have assessed this genetic factor
in a large, international, multicenter study of men with
and without TGCT.
Subjects and Methods
Subjects
We studied 4,441 males obtained from numerous
sources that we grouped into four categories (table 1),
as follows.
Familial studies.—The International Testicular Cancer
Linkage Consortium (ITCLC) has obtained genomic
DNA from at least one affected individual from 418
pedigrees with two or more members who have TGCT
(Rapley et al. 2000). The pedigree structures and the
sources of these families are shown in table 2. All cases
of TGCT with DNA sampled from TGCT pedigrees in
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Table 2
Characteristics of Pedigrees of ITCLC Probands
with Familial TGCT
Pedigree Characteristic
No. of
Pedigrees
Structure:
Father/son 69
Sibling pairs 182
Sibling trios 9
MZ twins 12
Uncle/nephew pairs (maternal and paternal) 37
Cousin pairs (maternal and paternal) 58
Grandfather/grandson 9
Half-sibling pairs 3
Families with 13 TGCT-affected members 37
Other pedigree structure 2
Proband ascertainment location:
Australia:
Melbourne 4
Sydney 19
Canada 24
Czech Republic 1
Denmark 9
France 5
Germany 23
Hungary 15
Ireland 3
Netherlands 7
Norway 34
Russia 1
Switzerland 2
United Statesa:
Penn and Indiana 21
NCI 18
USC 27
United Kingdom 205
a Penn p University of Pennsylvania; Indianap Univer-
sity of Indiana; NCI p National Cancer Institute; USC p
University of Southern California.
the ITCLC were genotyped in the present study; how-
ever, only the proband case designated by the local site
was counted for statistical analysis. Probands were index
cases from which the pedigree was ascertained. The
ITCLC has also collected genomic DNA from 61 males
affected with bilateral TGCT and 17 males with TGCT
and a family history of UDT—both groups without a
family history of TGCT. In addition, 35 probands with
a family history of TGCT were identiﬁed from one of
the case series described below, 10 of which were re-
ferred to the ITCLC and counted as one of their 418
pedigrees.
Case series.—From the United Kingdom, 682 TGCT-
affected patients without a family history were recruited
as members of two case series. The ﬁrst was a consec-
utive series of patients with TGCT who attended the
Royal Marsden National Health Service Trust Hospital
testicular cancer clinic (London) from 1996 onward. The
second case series was recruited from patients with
TGCT who attended the outpatient clinic at Cookridge
Hospital (Leeds) during the period from September 1999
to May 2002. In The Netherlands, 311 cases were col-
lected from 12 different hospitals in Rotterdam and sur-
rounding districts between 1991 and 2004. The 18 Hun-
garian cases were collected from the National Institute
of Oncology (Budapest) from 2001 to 2004. The 14
cases from Canada were patients at the Princess Mar-
garet Hospital Testis Clinic (Toronto) collected from
2002 to 2004.
Case-control series.—Consecutive cases of TGCT
were ascertained from the University of Pennsylvania
Health System (UPHS), and controls were ascertained
from UPHS GeneralMedicine and Student Health clinics
and were frequency-matched by age and race; 60% of
cases are incident, and the remainder are prevalent. The
Fred Hutchinson Cancer Research Center (FHCRC)
study is a population-based study of patients with ﬁrst
primary TGCT newly diagnosed between 1999 and
2002 among 18–44-year-old residents of three urban
counties of western Washington State. Control subjects
were frequency-matched by age and were ascertained
from the general population of the three counties by use
of random-digit telephone dialing. In the FHCRC study,
family history of TGCT was determined only among
ﬁrst-degree relatives. Because there were only a few in-
dividuals of minority ethnicity in these two studies, and
to remain consistent with the assumed predominate eth-
nicity of the case probands from other ascertainment
centers for whom ethnicity is unknown, only non-His-
panic whites from the two case-control studies were in-
cluded in the analyses.
Unaffected series.—Four series of otherwise healthy
white British males were identiﬁed. Series I consists of
male spouses of patients with cancer who attended the
Royal Marsden Hospital National Health Service Trust.
Series II consists of spouses of female patients who were
recruited as part of the National Cancer Research Net-
work Trial (1999–2002), the Royal Marsden National
Hospital Service Trust/Institute of Cancer Research
Family History and DNA Registry (1999–2004), or the
case-control Genetic Lung Cancer Predisposition Study
(1999–2004). Series III consists of male children from
the North Cumbria Community Genetics Project from
whom umbilical cord blood was obtained. Series IV con-
sists of human male random control DNA panels that
were purchased from the European Collection of Cell
Cultures. Donors were ethnically matched to cases (U.K.
whites) but were not age matched. Unaffected series
of healthy Hungarian males were recruited from the
Department of Physical Education and Sport at Sem-
melweis University (Budapest). In addition, 354 race-
matched but not age-matched, cancer-free males as-
certained through the UPHS General Medicine clinics
were genotyped. Regardless of the source, patients with
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TGCT and unaffected males donated biological samples
and medical information with fully informed consent
and local or national ethics review board approval.
Genotyping
We typed the gr/gr deletion by using a multiplex PCR
that ensured that a failure of PCR was not designated
as a deletion (see ﬁg. 1A). The STSs sY1201 (outside the
AZFc region) and sY1291 (a marker of the gr/gr dele-
tion) (see ﬁg. 1B) were ampliﬁed together in a 25-ml PCR
reaction. The PCR mix included 12.5 pmol of each
primer, 2.5 ml of 10#NH4/MgCl2 buffer (Taq-Pro DNA
Polymerase [Denville Scientiﬁc]), 6.25 nmol of each
dNTP, 15 ng of genomic DNA, and 1.25 U of Taq-Pro
DNA Polymerase. The PCR conditions were an initial
cycle at 95C for 5 min; 40 cycles at 95C for 30 s, 60C
for 30 s, and 72C for 30 s; and a ﬁnal step at 72C for
10 min (see NCBI UniSTS database for all PCR primer
sequences). The same conditions were used to type DNA
extracted from white blood cells and buccal swabs. A
total of 7 ml of the PCR product was sized on a 1%
agarose gel, with the use of a 100-bp ladder as a stan-
dard. All samples positive for the deletion were repeated
at least twice and were tested for sY1206 and sY1191
to determine whether they carried the larger AZFc or
the b1/b3 deletion, respectively (ﬁg. 1B) (Repping et al.
2004). One unaffected male with an AZFc deletion was
omitted from further analysis. All gr/gr deletion geno-
typing was performed at two centers—the Institute of
Cancer Research and the University of Pennsylvania.
The two centers typed 33 samples in common.
To determine whether gr/gr deletions occurred on the
same haplotype, we genotyped the markers (in sequence
order) DYS393, DYS19, DYS391, DYS390, DYS385a,
DYS385b, and DYS392 for cases and controls demon-
strating a gr/gr deletion (Ensembl and National Center
for Biotechnology InformationWeb sites). Markers were
end-labeled with [g-32P] ATP by use of T4 polynucleotide
kinase, were ampliﬁed under standard conditions, and
were electrophoresed on standard denaturing polyacryl-
amide gels, dried, and exposed to x-ray ﬁlm. All samples
were run across a single gel (per marker), to allow easy
comparison of alleles between samples.
Statistical Analysis Methods
We classiﬁed each patient with TGCT on the basis of
the histological diagnosis of his tumor: seminoma or
nonseminoma germ cell tumor (NSGCT, including cho-
riocarcinoma, embryonal, teratoma, and mixed cell-type
TGCT), and we included only gonadal primaries. Since
the Y chromosome is hemizygous, we could determine
whether affected family members shared a common Y
chromosome by examination of the pedigree. We des-
ignated an inheritance pattern of “paternal lineage” for
those probands who had at least one affected male rel-
ative who shared the same Y chromosome (i.e., identical
by descent). In contrast, “maternal lineage” designated
probands with affected male relatives who did not share
a common Y chromosome.
All analyses were performed using SAS v9.1 (SAS In-
stitute). Using unconditional logistic regression, we de-
termined odds ratio (OR) estimates as measures of the
relative risk of TGCT associated with the gr/gr deletion
after adjustment for geographic region or ascertainment
center (Philadelphia, western Washington State, other
North America, Hungary, United Kingdom, and other
Europe or Australia; hereafter referred to collectively as
“study centers”); 95% CIs around the ORs were esti-
mated using the logarithmic transformation and asymp-
totic theory. Data on study centers were entered in the
model as a series of indicator variables. To estimate and
compare the associations for the outcomes of familial
versus sporadic TGCT, seminoma versus NSGCT, and
paternal versus maternal lineage, we used a multinomial
logit model to obtain simultaneously the OR and 95%
CI for the association between the gr/gr deletion and
each level of outcome, adjusting for study center. Age
at diagnosis of TGCT was compared nonparametrically
using the Kruskal-Wallis test.
Results
After adjustment for study center, TGCT cases were
signiﬁcantly more likely to carry the gr/gr deletion,
compared with unaffected males (aOR p 2.1; 95% CI
1.3–3.6; ) (table 3). Among the study centersPp .005
contributing both TGCT cases and unaffected males to
the analysis, the distribution of the gr/gr deletion did not
differ ( ; 3 df; ). The center-speciﬁc ORs2x p 3.3 Pp .35
were 1.7 (western Washington State; 95% CI 0.58–5.0),
1.8 (Hungary; 95% CI 0.37–8.6), 2.3 (United Kingdom;
95% CI 1.1–4.7), and 2.8 (Philadelphia; 95% CI 0.66–
12). When analysis was restricted to these centers, the
center-adjusted OR was very similar to that which in-
cluded all data (aOR 2.1; 95% CI 1.3–3.5). In an anal-
ysis restricted to the two case-control studies that con-
currently enrolled healthy controls and cases without
selection for family history, the estimated center-adjusted
OR was 2.3 (95% CI 0.89–6.2).
TGCT cases with a family history of TGCT were
more likely to carry the gr/gr deletion than those with-
out a family history (3.0% vs. 2.0%, respectively). In
comparisons with unaffected males, the center-adjusted
OR associated with carriage of the gr/gr deletion was
3.2 (95% CI 1.5–6.7; ) for cases with a fam-Pp .0027
ily history and 1.9 (95%CI 1.1–3.3; ) for casesPp .024
without a family history. These OR estimates were not
statistically different from one another ( ). Com-Pp .16
parable results for analyses were obtained after the 12
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Figure 1 A, Genotyping of the gr/gr deletion by multiplex PCR of sY1291 and sY1201. B, STSs used to test for the presence of the
gr/gr deletion on the Y chromosome and in the ampliconic structure of the AZFc region.
MZ twin probands from the case group were included
(results not shown). For TGCT cases demonstratingma-
ternal lineage, the prevalence of the gr/gr deletion was
8.6%, whereas, among those with paternal lineage, the
prevalence was only 1.7%. The center-adjusted asso-
ciation of the gr/gr deletion was greatly elevated for
probands with evidence of maternal lineage (OR 9.8;
95%CI 3.5–27) and was statistically different from that
for probands with evidence of paternal lineage (OR 1.6;
95% CI 0.52–4.8; for comparison of trans-Pp .0019
mission-speciﬁc ORs).
The association between gr/gr and TGCT was stron-
ger for cases of seminoma than for NSGCT cases (sem-
inoma: aOR 3.0; 95% CI 1.6–5.4; NSGCT: aOR 1.5;
95% CI 0.72–3.0; for comparison of aORs).Pp .041
Presence of the gr/gr deletion was not associated with
an earlier mean age at diagnosis overall (33 vs. 32 years
for gr/gr deletion carriers and noncarriers, respectively;
) or within histologic type (data not shown).Pp .33
Personal history of UDT could be determined for 1,263
TGCT cases. The proportion of gr/gr deletion carriers
was similar among cases with a personal history of UDT
(3/123) and those without (32/1,140). The gr/gr deletion
was identiﬁed in 1 of 92 bilateral TGCT cases without
a family history of TGCT and in none of the 39 cases
of solitary TGCT with a family history of UDT.
Y haplotyping was performed on 29 TGCT cases and
nine unaffected males who demonstrated a gr/gr dele-
tion. Among the TGCT cases, 13 had a family history
of disease (7 cases from the United Kingdom, 3 from
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Table 3
Associations of the Y Deletion gr/gr and TGCT
SUBJECT GROUP
gr/gr
DELETION
OR (95% CI) aORa (95% CI) aORb (95% CI)n %
Unaffected menc ( )np 2,599 33 1.3 1.0 1.0 1.0
TGCT cases ( ):np 1,842 42 2.3 1.8 (1.1–2.9) 2.1 (1.3–3.6) 2.1 (1.3–3.5)
Positive family historyd ( )np 431 13 3.0 2.4 (1.3–4.6) 3.2 (1.5–6.7) 2.9 (1.2–6.9)
Negative family historyd ( )np 1,376 28 2.0 1.6 (.97–2.7) 1.9 (1.1–3.3) 1.9 (1.1–3.4)
Paternal lineagee ( )np 345 6 1.7 1.4 (.57–3.3) 1.6 (.54–5.0) 1.7 (.50–5.9)
Maternal lineagee ( )np 80 7 8.8 7.5 (3.2–17) 9.8 (3.5–27) 9.4 (3.0–29)
Seminomaf ( ):np 827 27 3.3 2.6 (1.6–4.4) 3.0 (1.6–5.4) 2.8 (1.4–5.2)
Positive family history ( )np 146 6 4.1 3.3 (1.4–8.1) 3.3 (1.2–9.4) 2.3 (.51–9.9)
Negative family history ( )np 660 20 3.0 2.4 (1.4–4.3) 2.7 (1.4–5.2) 2.8 (1.5–5.5)
Nonseminomaf ( ):np 806 13 1.6 1.3 (.67–2.4) 1.5 (.72–3.0) 1.7 (.79–3.5)
Positive family history ( )np 145 5 3.5 2.8 (1.1–7.2) 4.9 (1.7–14) 4.0 (1.1–14)
Negative family history ( )np 653 8 1.2 .96 (.44–2.1) 1.3 (.55–3.0) 1.4 (.60–3.3)
a Adjusted for study center (Philadelphia, western Washington State, other North America, Hungary, United
Kingdom, and other Europe or Australia).
b Includes only those study centers that contributed both patients with TGCT and unaffected men (Hungary,
Philadelphia, United Kingdom, and western Washington State) and is adjusted for those study centers.
c Reference group for all comparisons.
d Information on family history of TGCT was not available for 23 cases (17 seminoma and 6 nonseminoma),
including 1 gr/gr deletion carrier. In addition, 12 cases (4 seminoma, 2 nonseminoma, and 6 of unknown tumor
type) with an affected MZ twin were excluded from analyses of family history.
e Information on six TGCT cases with a family history (one from the ITCLC familial studies and ﬁve from
the case-control studies) was insufﬁcient to determine the type of Y-chromosome transmission.
f Information on tumor type was not available for 209 TGCT cases, including 2 gr/gr deletion carriers.
Norway, 2 from Hungary, and 1 from Australia), and
16 had no family history (14 from the United Kingdom
and 2 from Canada). All unaffected males were from
the U.K. series. Of the 38 samples tested, a total of 23
different haplotypes were seen, with each haplotype dif-
fering by at least one microsatellite marker. Six haplo-
types were observed twice, and one haplotype was ob-
served in three samples. Of the six shared haplotypes
observed twice, two were present in one control and
one case sample (all samples from the United Kingdom),
three were observed in case samples only (haplotype 3
was seen in two Norwegian cases with a family history,
haplotype 4 was present in a U.K. case with a family
history and in a single Canadian case, and haplotype 5
was seen in two single U.K. cases), and one was detected
in a control sample only. The haplotype observed three
times was seen in the two Hungarian cases with a fam-
ily history and in one U.K. case with no family his-
tory. When we examined separately the subgroup of Y
haplotypes from U.K. cases and unaffected males, 26
haplotypes were observed that differed by at least one
microsatellite. More conservatively, we observed 19
haplotypes in which allele size differed at three or more
microsatellites. The allele frequencies for each micro-
satellite marker did not differ signiﬁcantly between the
U.K. cases with the gr/gr deletion and the U.K. unaf-
fected males with the gr/gr deletion.
Transmission of the gr/gr deletion could be evaluated
in only nine cases (six paternal lineage and three ma-
ternal lineage) by genotyping other male family mem-
bers who shared a Y chromosome. In paternal lineage
cases, we could demonstrate the transmission of the gr/
gr deletion between affected cases (usually fathers or
siblings), either by demonstration of the deletion in both
affected individuals or by the presence of the deletion
in unaffected male relatives in the Y lineage between
affected cases. In cases with maternal lineage, trans-
mission of the gr/gr deletion was demonstrated to or
from another unaffected male relative who shared a Y
chromosome. All cases but one demonstrated trans-
mission of the gr/gr deletion. In one sib pair, one brother
carried the gr/gr deletion, and the other did not. DNA
was unavailable from the father of these siblings; how-
ever, Y haplotyping and genomewide relationship test-
ing showed that these brothers were full siblings, sug-
gesting a de novo origin of the gr/gr deletion. In this
case, the brother with the gr/gr deletion was not the
proband designated by the referring institution and thus
was not counted as part of the statistical analyses.
Discussion
Our study demonstrates that the gr/gr deletion is asso-
ciated with a twofold increased risk of TGCT, which
increases to a threefold risk among patients with a family
history of disease. The observed associationwas stronger
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Table 4
Case-Only Associations of the Y Deletion gr/gr and Family History of TGCT
CHARACTERISTIC
OF TGCT CASESa
gr/gr
DELETION
OR (95% CI) aORb (95% CI)n %
Negative family historyc ( )np 1,376 28 2.0 1.0 1.0
Positive family history ( ):np 431 13 3.0 1.5 (.77–2.9) 1.7 (.81–3.4)
Paternal lineaged ( )np 345 6 1.7 .85 (.35–2.1) .97 (.38–2.4)
Maternal lineaged ( )np 80 7 8.8 4.6 (2.0–11) 5.2 (2.1–13)
a Information on family history of TGCT was not available for 23 cases. In addition,
12 cases with an affected MZ twin were excluded from analyses of family history.
b Adjusted for study center (Philadelphia, western Washington State, other North
America, Hungary, United Kingdom, and other Europe or Australia).
c Reference group for all comparisons.
d Information on six TGCT cases with a family history (one from the ITCLC familial
studies and ﬁve from the case-control studies) was insufﬁcient to determine the type of
Y-chromosome transmission.
for seminoma than for NSGCT cases. There was no
evidence of an association between the deletion and the
presence of UDT or bilateral disease. We could not di-
rectly determine the relationship between TGCT, infer-
tility, and the gr/gr deletion in our study, because most
centers did not collect information about fertility status.
The association between the gr/gr deletion and TGCT
case status was seen within each study center from
which cases and unaffected males were genotyped, but,
because of the rarity of both the disease and the gr/gr
deletion, the P values for the comparisons were most
signiﬁcant when the sample populations were com-
bined. Although our conclusions are limited to white
males of European ancestry, individuals from this pop-
ulation constitute the vast majority of TGCT cases di-
agnosed around the world (Ferlay et al. 2004). In the
United States, white patients account for 94% of all
TGCT cases (Ries et al. 2004).
The frequency of the gr/gr deletion was higher among
cases with a positive family history of TGCT than
among those without a recorded family history. Pro-
bands from families demonstrating maternal lineage
were at greater risk than probands from families dem-
onstrating paternal lineage. Although this result may be
somewhat counterintuitive, the gr/gr deletion impacts
male fertility, which may reduce the number of families
with the potential for paternal lineage. In addition, the
estimate of the gr/gr deletion association among pro-
bands with evidence of maternal lineage, though strong,
is imprecise because of the small numbers in this sub-
group. It is likely that the gr/gr deletion does not act in
isolation to increase TGCT risk and that additional ge-
netic and/or environmental factors, which may also
cluster in families, operate in concert with the deletion.
Since unaffected men are not at risk for becoming a
positive-family-history TGCT case, we reran analyses
of family history of TGCT and “lineage” among cases
only (see table 4). The results support those given in
table 3.
Several aspects of our study limit the strength of our
inferences. First, only 15% of cases and 23% of un-
affected males were drawn from designed epidemiologic
case-control studies with contemporaneous participant
recruitment. Although the comparability of ascertained
unaffected males to TGCT cases in the remaining study
centers is less certain—and potentially could have in-
troduced bias into our ﬁndings—we found similar as-
sociations regardless of the source of TGCT cases and
the reference group.
Even though it is not possible to rule out the effect
of population stratiﬁcation in our study, it is not likely
that this bias greatly impacted our results. Foremost,
we successfully reproduced our overall association be-
tween the gr/gr deletion and TGCT among several sub-
groups that were roughly deﬁned by geographic area of
ascertainment, the only proxy measure for race/ethnic-
ity that is available for all subjects in the present study.
Furthermore, our association was noted separately in
the two epidemiological case-control studies.
Although large-scale Y haplotyping of all 4,441 study
subjects is beyond the scope of the current analysis, we
attempted to determine whether the gr/gr deletion is
inherited on a unique background Y haplotype, by eval-
uating seven microsatellite loci in a proportion of gr/gr
deletion–carrying TGCT cases and unaffected males.
Despite that microsatellite markers are not as evolu-
tionarily stable as SNP markers, variation at several of
these loci would indicate that most gr/gr deletions ob-
served arose on a different Y-chromosome background.
Haplotyping of these markers strongly suggested that
the majority of deletions arose on different haplotypes
and not from a common founder haplotype. Among 38
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individuals tested, 123 different Y haplotypes were ob-
served; only 7 were observed more than once and only
1 of those was seen in three individuals. Even after lim-
iting haplotype analysis to a more homogenous group
and applying a more stringent criterion to deﬁne hap-
lotypic difference (dissimilar allele sizes at three or more
markers), we found 19 different haplotypes among the
29 TGCT cases and unaffected controls ascertained in
the United Kingdom. Our observation of the gr/gr de-
letion arising on multiple distinct Y haplotypes is con-
sistent with the data from Repping et al. (2003). We
believe that, although bias due to population stratiﬁ-
cation cannot be completely ruled out, our data sug-
gest that a clear bias introduced by the segregation of
Y haplotypic background within the different ethnic
groups that comprise white individuals of European de-
scent is unlikely.
Finally, although the sample size was very large
(particularly for a relatively rare cancer), the rarity of
the Y-chromosome microdeletion led to relatively wide
CIs. As such, it will be important to verify this ﬁnding
in an independent sample and to do so speciﬁcally
among patients who have TGCT with a positive fam-
ily history—the group in which we observed the stron-
gest evidence of association. However, because familial
TGCT is extremely uncommon and, to our knowledge,
there are no other extant TGCT study populations large
enough to test our hypothesis, conﬁrmation in the near
future seems unlikely.
Our data provide evidence that the gr/gr deletion is
a risk factor for TGCT, suggesting a novel role for mi-
crodeletions of the Y chromosome in addition to infer-
tility. The gr/gr deletion does not completely eliminate
any of the testis-speciﬁc genes or transcription-unit fam-
ilies, but it does reduce the copy number of several
genes, removing two of the four copies of theDAZ gene,
one of three copies of BPY2 (basic charge, Y-linked 2
[MIM 400013]), and one of two copies of CDY1. All
these genes are speciﬁcally expressed in male germ cells
and have roles in male germ cell development and dif-
ferentiation (Reijo et al. 1995, 1996, 2000; Saxena et
al. 1996; Kleiman et al. 2003; Ginalski et al. 2004).
DAZ and CDY1 have been selectively maintained on
the Y chromosome (Dorus et al. 2003) and encode
RNA-binding proteins expressed in premeiotic sper-
matagonia (Reijo et al. 1995; Reynolds and Cooke
2005) and a protein with histone acetyltransferase ac-
tivity (Lahn et al. 2002), respectively. The function of
these genes in the maintenance of normal germ cell ac-
tivity is incompletely understood, and future work is
needed to better characterize the impact of copy loss on
germ cell development and differentiation, which may
result in a higher risk of neoplasia.
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